Why the study?
Cellular factors that modify the activity of soluble guanylyl cyclase present an opportunity to improve the effectiveness of existing targeted drugs and develop new therapeutic strategies.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Cellular factors modulating sGC merit study; leaves open targeted NO-cGMP therapies in cardiovascular disease.
NO-stimulated guanylyl cyclase (SGC) is a hemoprotein that plays key roles in various physiological functions. SGC is a typical enzyme-linked receptor that combines the functions of a sensor for NO gas and cGMP generator. SGC possesses exclusive selectivity for NO and exhibits a very fast binding of NO, which allows it to function as a sensitive NO receptor. This review describes the effect of various cellular factors, such as additional NO, cell thiols, cell-derived small molecules and proteins on the function of SGC as cellular NO receptor. Due to its vital physiological function SGC is an important drug target. An increasing number of synthetic compounds that affect SGC activity via different mechanisms are discovered and brought to clinical trials and clinics. Cellular factors modifying the activity of SGC constitute an opportunity for improving the effectiveness of existing SGC-directed drugs and/or the creation of new therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Sharina et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: